Recent Updates
Recently added Catalysts

V540D

Phase 1

Healthy | Monoclonal antibody | Other |Merck & Company, Inc.|Last Updated: Mar 13, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment72
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06688058A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)PHASE1 ACTIVE NOT_RECRUITING 72Dec 20, 2024Nov 30, 2026Mar 13, 20264 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)
Up to approximately 6 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Number of Participants Who Experience a Solicited Systemic AE
Up to approximately 6 months

Solicited systemic AEs include headache, fatigue, nausea, dizziness, muscle aches, joint pain.

Number of Participants Who Experience Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Up to approximately 6 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Number of Participants Who Experience Unsolicited AEs
Up to approximately 7 months

An unsolicited AE is an event that is not predefined as a solicited AE or is predefined as a solicited AE but reported at any time outside the solicited time period.

Number of Participants Who Experience a Serious Adverse Event (SAE)
Up to approximately 18 months

SAEs include AEs that result in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect.

Number of Participants Who Experience a Medically-Attended AE (MAAE)
Up to approximately 18 months

AEs in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Routine visits are not considered MAAEs. Examples of routine visits include physical examination, wellness visits, or vaccinations.

Number of Participants Who Experience an Event of Clinical Interest (ECI)
Up to approximately 18 months

ECIs are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs).

Secondary Endpoints
Total Immunoglobulin G (IgG) Geometric Mean Ratios (GMRs) for anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Up to approximately 7 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
V540DEXPERIMENTALParticipants will receive vaccinations with V540D.
GARDASIL®9ACTIVE_COMPARATORParticipants will receive vaccinations with GARDASIL®9.
Interventions
NameTypeDescription
V540DBIOLOGICALExperimental vaccine and adjuvant administered via intramuscular (IM) injection
GARDASIL®9BIOLOGICALSuspension administered via IM injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites4

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health based on medical history, physical examination, vital sign (VS) measurements and electrocardiograms (ECGs) performed before randomization Exclusion Criteria: The key exclusion criteri...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06688058primaryCompletionDate: changed
LOWMay 24, 2026NCT06688058studyFirstPostDate: changed